Answers are grounded in this paper and cite their sources.
Systematic review integrates genomic tools for hemoglobinopathy screening and prevention in at-risk populations, suggesting pathways for improved care.
Hemoglobinopathies remain one of the most consequential inherited disorders in perinatal medicine, yet the rapid expansion of genomic technologies has outpaced current clinical frameworks in many high-prevalence regions. This systematic review synthesizes evidence across cell-free DNA (cfDNA)-based assays, expanded carrier screening (ECS), preimplantation genetic testing (PGT) for monogenic disorders, and emerging sequencing platforms to clarify how these tools can be integrated into a coherent prenatal pathway. A comprehensive search of major databases identified 1284 records, from which 35 studies met the inclusion criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided screening and full-text evaluation. The included literature spans methodological innovations, clinical validation studies, program-level evaluations, and reproductive interventions relevant to α- and β-thalassemia. Across studies, three themes emerged. First, noninvasive genomic technologies have advanced substantially: haplotype-based noninvasive prenatal testing demonstrated high concordance for monogenic diagnosis, while deletion-based cfDNA assays reliably identified common α-thalassemia variants. Second, ECS and PGT-M are increasingly feasible in low-resource settings, offering early opportunities for prevention when supported by adequate laboratory infrastructure and counseling services. Third, advanced platforms such as long-read sequencing and prenatal ES/GS show promise for resolving complex or atypical genotypes, though their routine prenatal use remains limited by cost, turnaround time, and bioinformatic complexity. Despite heterogeneity in study design, the collective evidence supports a staged, population-to-pregnancy pipeline that integrates screening, diagnosis, and reproductive planning. The review highlights persistent gaps – including limited data from Southeast Asia, variable analytic standards, and ethical challenges surrounding incidental findings – and underscores the need for coordinated policies to ensure equitable implementation of prenatal genomics in hemoglobinopathy-endemic regions.
No takes yet. Share an insight, caveat, or question.
Andonotopo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: